Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy

Phase 2

Terminated

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: O6-benzylguanine
Drug: temozolomide

First Posted Date: 2007-02-19

Last Posted Date: 2017-03-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT00436436

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
🇺🇸
NCI - Neuro-Oncology Branch, Bethesda, Maryland, United States

AZD2171 to Treat Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Procedure: Magnetic Resonance Imaging (DCE-MRI)
Drug: AZD2171
Drug: Prednisone

First Posted Date: 2007-02-19

Last Posted Date: 2018-10-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 59

Registration Number: NCT00436956

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Sorafenib in Treating Patients With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: sorafenib tosylate
Other: pharmacological study
Procedure: assessment of therapy complications
Other: laboratory biomarker analysis

First Posted Date: 2007-02-19

Last Posted Date: 2014-02-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 110

Registration Number: NCT00436579

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Human Papillomavirus (HPV) and Risk of Cervical Precancer and Cancer

Completed

Conditions: Cervical Neoplasia

First Posted Date: 2007-02-14

Last Posted Date: 2020-05-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 131110

Registration Number: NCT00435214

Locations: 🇺🇸
Kaiser Permanente Northern California, Oakland, California, United States

Physical Therapy Trial for Pelvic Pain

Not Applicable

Completed

Conditions: Chronic Prostatitis
Chronic Pelvic Pain Syndrome
Interstitial Cystitis
Painful Bladder Syndrome

Interventions: Other: Global Therapeutic Massage (GTM)
Other: Myofascial physical therapy (MPT)

First Posted Date: 2007-02-13

Last Posted Date: 2022-12-12

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 47

Registration Number: NCT00434343

Locations: 🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States

and more 2 locations

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Phase 3

Active, not recruiting

Conditions: Breast Adenocarcinoma

Interventions: Drug: Cyclophosphamide
Biological: Bevacizumab
Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Other: Placebo Administration
Other: Quality-of-Life Assessment

First Posted Date: 2007-02-12

Last Posted Date: 2025-06-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 4994

Registration Number: NCT00433511

Locations: 🇺🇸
North Suburban Medical Center, Thornton, Colorado, United States
🇺🇸
Northeast Alabama Regional Medical Center, Anniston, Alabama, United States
🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

and more 836 locations

Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma

Phase 2

Completed

Conditions: Recurrent Adult Brain Neoplasm
Adult Glioblastoma
Adult Gliosarcoma

Interventions: Biological: Bevacizumab
Drug: Irinotecan Hydrochloride
Drug: Temozolomide

First Posted Date: 2007-02-12

Last Posted Date: 2018-09-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 123

Registration Number: NCT00433381

Locations: 🇺🇸
Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
🇺🇸
Mercy Hospital, Coon Rapids, Minnesota, United States
🇺🇸
Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States

and more 90 locations

Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery

Phase 1

Completed

Conditions: Adenocarcinoma of the Rectum
Stage I Colon Cancer
Stage I Rectal Cancer
Stage II Colon Cancer
Stage II Rectal Cancer
Stage III Colon Cancer
Adenocarcinoma of the Colon
Stage III Rectal Cancer

Interventions: Drug: resveratrol
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2007-02-12

Last Posted Date: 2014-09-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT00433576

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Stage III Mantle Cell Lymphoma
Stage IV Mantle Cell Lymphoma
Contiguous Stage II Mantle Cell Lymphoma
Stage I Mantle Cell Lymphoma
Noncontiguous Stage II Mantle Cell Lymphoma

Interventions: Drug: bortezomib
Biological: rituximab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: vincristine
Drug: dexamethasone
Biological: filgrastim
Biological: pegfilgrastim
Procedure: Autologous stem cell transplantation (ASCT)

First Posted Date: 2007-02-12

Last Posted Date: 2014-10-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 77

Registration Number: NCT00433537

Locations: 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

Insulin Sensitivity in Men With the Metabolic Syndrome

Not Applicable

Suspended

Conditions: Metabolic Syndrome

Interventions: Procedure: intravenous glucose tolerance test
Procedure: aerobic capacity (VO2 Max)
Drug: testosterone
Procedure: MRI
Drug: goserelin acetate implant
Drug: anastrozole
Procedure: muscle biopsy
Procedure: measurement of resting metabolic rate (energy expenditure)
Procedure: Dual energy x-ray absorptiometry
Procedure: Fasting oral glucose tolerance test

First Posted Date: 2007-02-09

Last Posted Date: 2010-03-02

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 72

Registration Number: NCT00433173

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy